Indaptus Therapeutics, Inc.

Stage 2 · Advancing · week 1⚡ 1→2 transition today

As of Oct 22, 2026, Indaptus Therapeutics is in Stage 2, the uptrend phase, now in its first week (since Oct 22, 2026). It closed at $2.99, 37.1% below its 52-week high and above its 200-day average, which is rising.

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. More about the company

$2.99

-7.43% today

$398M · Small cap

Market Neutral — Fading

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is INDP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 88w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S2 13w → S3 6w → S4 11w → S1 7w → S2 9w → S3 7w → S4 88w → S1 4w → S4 2w → S1 1w → S2 2w → S1 1w → S2 4w → S3 1w → S4 5w → S1 3w → S2 1w current

Total tracked: 164 weeks across 18 stage runs.

INDP among Biotechnology235th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…235	INDPIndaptus Therapeutics, Inc.	Stage 2 · wk 1	42	−20.7%

vs 52W High

-37.1%

$0.94 lo$4.75 hi

37.1% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 1

1w13w26w

Week 1, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

31.0%

200 DMA: $2.28 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.20x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-20.7%

+14.6%

-5.1%

YTD

+9.1%

-16.7%

Scan Membership

Breakout Watch

Latest: 2024-04-30

4 appearances in last 60 days. First seen: 2018-11-14.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S21→2

Wk 1 · Vol 0.20x

2026-10-21S1

Wk 3 · Vol 0.47x

2026-10-20S1

Wk 3 · Vol 0.20x

2026-10-19S1

Wk 3 · Vol 0.16x

2026-10-16S1

Wk 3 · Vol 0.45x

2026-10-15S1

Wk 3 · Vol 1.24x

2026-10-14S1

Wk 2 · Vol 0.42x

2026-10-13S1

Wk 2 · Vol 0.11x

2026-10-12S1

Wk 2 · Vol 0.34x

2026-10-09S1

Wk 2 · Vol 0.45x

2026-10-08S1

Wk 2 · Vol 0.49x

2026-10-07S1

Wk 1 · Vol 0.57x

Moving averages & range

50 DMA

$2.28

200 DMA

$2.28

52W High

$4.75

52W Low

$0.94

5D Low

$2.63

Resistance levels (recent highs)

20d High

$3.85

60d High

$4.00

120d High

$4.75

250d High

$4.75

Next resistance

+28.8%

to 20d High

ROE

-318.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 35.2

Indaptus Therapeutics: quick answers

What stage is Indaptus Therapeutics in?

As of Oct 22, 2026, Indaptus Therapeutics (INDP) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Indaptus Therapeutics in an uptrend?

Yes. Indaptus Therapeutics is in a Stage 2 uptrend. It trades 31.0% above its 200-day average, which is rising.

How far is Indaptus Therapeutics from its 52-week high?

Indaptus Therapeutics closed at $2.99 on Oct 22, 2026, 37.1% below its 52-week high of $4.75. Its 52-week low is $0.94.

How has Indaptus Therapeutics performed over the past year?

As of Oct 22, 2026, Indaptus Therapeutics is down 16.7% over the past year and up 9.1% so far in 2026.

Which sector and industry is Indaptus Therapeutics in?

Indaptus Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.